Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496171 | 1.00 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10527716 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14510730 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30496159 | 0.80 | ALDH1A1 (0.53) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1161590 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25198363 | 0.80 | ALDH1A1 (0.53) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15436874 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3791629 | 0.80 | HPGD (0.51) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7213726 | 0.77 | HPGD (0.49) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3660182 | 0.77 | NPC1 (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-05-08 | — | — | US | disclosed |
| CN-117720518-B | Benzimidazole compound, preparation method thereof, pharmaceutical composition and application | 江苏海洋大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-4387617-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117720518-A | Benzimidazole compound, preparation method thereof, pharmaceutical composition and application | 江苏海洋大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-111417394-B | Benzimidazole derivatives and uses thereof | 帝人制药株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-115536579-B | Tyrosine kinase inhibitor and preparation method and application thereof | 江苏海洋大学 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115536579-A | Tyrosine kinase inhibitor and preparation method and application thereof | 江苏海洋大学 | 2022-12-30 | — | — | CN | disclosed |
| CN-107266449-B | Process for the preparation of chiral 8- (3-amino-piperidin-1-yl) -xanthines | 勃林格殷格翰国际有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007014886-A1 | HYDROCHLORIDES AND HYDRATES OF 1-[(3-CYANOPYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-AMINOPIPERIDIN-1-YL)XANTHINE, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014886-A1 | HYDROCHLORIDES AND HYDRATES OF 1-[(3-CYANOPYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-AMINOPIPERIDIN-1-YL)XANTHINE, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006048427-A1 | METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048427-A1 | METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | ASAH2, ASAH1, ACER2 | HPGD 1129/4885CYP1A2 2685/4885CYP2D6 3316/4885 |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | PDE8B, PDE8A, XDH | HPGD 1203/4885CYP1A2 75/4885CYP2D6 101/4885 |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | DPP4, DPP7, DPP8 | HPGD 1325/4885CYP1A2 262/4885CYP2D6 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.